Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Portfolio Pulse from Vandana Singh
Merck has filed a lawsuit against the U.S. government to halt the implementation of the Medicare drug price negotiation program outlined in the Inflation Reduction Act, calling it 'extortion'. The law aims to achieve annual savings of $25 billion by 2031 through negotiations on drug prices covered by Medicare.
June 06, 2023 | 7:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie's Imbruvica is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026, potentially impacting its revenue.
AbbVie's Imbruvica is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026. If the Inflation Reduction Act is implemented, it could lead to lower drug prices, which may negatively impact AbbVie's revenue.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Bristol Myers Squibb's Eliquis is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026, potentially impacting its revenue.
Bristol Myers Squibb's Eliquis is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026. If the Inflation Reduction Act is implemented, it could lead to lower drug prices, which may negatively impact Bristol Myers Squibb's revenue.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Merck files a lawsuit against the U.S. government over the Medicare drug pricing program, potentially impacting its profits and future drug development.
Merck's lawsuit against the U.S. government over the Medicare drug pricing program could negatively impact its profits and hinder the development of innovative treatments. The company claims the law would force drug manufacturers to negotiate prices below market value, which could result in reduced profits.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer's Ibrance is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026, potentially impacting its revenue.
Pfizer's Ibrance is expected to be among the top-selling drugs subject to U.S. price negotiations for 2026. If the Inflation Reduction Act is implemented, it could lead to lower drug prices, which may negatively impact Pfizer's revenue.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50